Bregal Milestone Backs Nethive With Majority Growth Investment and JoyComm Acquisition
22.10.2026 10:00:00 CEST | Business Wire | Press Release
Bregal Milestone, a leading European software growth private equity firm, today announced a majority growth investment in Nethive S.p.A. (“Nethive” or the “Company”), a leading Italian cybersecurity services and software provider. Alongside its investment in Nethive, Bregal Milestone has also backed Nethive’s acquisition of IT security specialist Joy Comm S.r.l. (“JoyComm”).
Founded in 2014 by Alessandro Bellato and Diego Rocco, Nethive has become a trusted cybersecurity partner to blue-chip enterprises, SMEs, and public-sector organizations across Italy. Its platform spans managed security services, professional services and technology resale, helping organizations protect critical infrastructure and networks, strengthen cyber resilience and reduce operational complexity.
Nethive combines deep technical expertise with 24/7 monitoring, threat detection and response, risk and vulnerability management, infrastructure protection and specialist consultancy. The Company serves more than 250 clients, building a reputation for responsiveness and reliability in mission-critical environments across telecommunications, energy, healthcare, industrials and public administration. Nethive also develops proprietary carrier-grade software: HiveFlow, which enables telecom operators to deliver network-based security services, and X-Suite, for monitoring and log management of complex network infrastructures.
JoyComm brings complementary expertise and a strong track record to Nethive, strengthening the Company's capabilities across cybersecurity, IT/OT networking and cloud infrastructure. The inclusion of JoyComm extends Nethive’s specialized skills, advanced security consulting and broader technological capabilities to support customers in increasingly complex and critical environments.
In recent years, Nethive has delivered significant growth, with revenue reaching c.€25 million in 2026 (2020-26 CAGR of c.30%) and headcount growing from c.20 to over 80 (2026 figures pro-forma consolidated, including JoyComm). This performance was recognized in the Financial Times’ Europe’s Long-term Growth Champions 2026 list, where Nethive was the highest-ranked Italian company in the IT & Software category.
With Bregal Milestone's support, Nethive will accelerate its growth by investing in AI-enabled automation, expanding its managed services and proprietary software offerings, strengthening its commercial organization, and pursuing selective strategic acquisitions in Italy and beyond.
“The cybersecurity landscape is evolving rapidly: threats are becoming more sophisticated, regulations are tightening across Europe, and AI is increasing both the scale and complexity of cyberattacks. We founded Nethive to help organizations manage this complexity with confidence. Bregal Milestone’s deep cybersecurity expertise makes them the ideal partner for our next phase of growth. Their support will help us further productize our offering and expand our footprint while preserving the reliability and quality our clients expect,” said Alessandro Bellato and Diego Rocco, Co-Founders and Co-CEOs of Nethive.
“We have been impressed by what Alessandro, Diego and the entire Nethive team have accomplished over the years and are delighted to partner with them to support this next phase of the Company’s growth,” added Philippe Lautenberg, Co-Founder and Managing Partner at Bregal Milestone. “The Italian and European cybersecurity markets are undergoing a significant transformation, and we are convinced that Nethive is ideally positioned to capture the opportunities ahead.”
Alvarez & Marsal, PedersoliGattai and Fineurop Soditic acted as financial, legal and M&A and debt advisors to Bregal Milestone, respectively. Deloitte acted as financial and legal advisor to Nethive's shareholders, assisting them on legal aspects and vendor due diligence. Klecha & Co. acted as the exclusive financial advisor to the shareholders of Nethive. Terms of the transaction were not disclosed.
About Bregal Milestone
Bregal Milestone is a leading software and technology private equity firm with c.€2.3 billion of capital raised since inception. The firm provides growth capital and operational support to build market-leading companies in B2B software, AI and cybersecurity. Bregal Milestone is part of Bregal, a global GP solutions platform for the private markets with assets under management of over €24 billion. Bregal Milestone was recognized by GrowthCap as one of the Top Private Equity Firms of 2026. For more information, visit www.bregalmilestone.com or follow us on LinkedIn.
About Nethive
Nethive S.p.A. is a leading Italian cybersecurity provider serving enterprise, SME and public-sector customers. Nethive delivers managed security services, professional services, technology resale and proprietary software, supporting more than 250 clients across telecommunications, energy, healthcare, industrials and public administration. For more information, visit http://www.nethive.it or follow us on LinkedIn.
About JoyComm
Joy Comm is an Italian cybersecurity and IT/OT networking specialist providing the design, implementation and management of secure network and cloud infrastructures. For more information, visit https://www.joycomm.eu/ or follow us on LinkedIn.
Disclosure: Endorsements presented herein are made by current or former portfolio company executives, over which Bregal Milestone may have the ability to exercise discretion on employee compensation, promotion and other employment decisions and may also be investors in Bregal funds.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261021136081/en/
Contacts
For Bregal Milestone:
Siqi Wu
Marketing & Communications Manager
siqi.wu@bregal.com
For Nethive:
Giulia Masin
Marketing Manager
g.masin@nethive.it
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom